Mesalazine-induced aplastic anemia.
Wiesen
Ari
A
Wiesen
Jonathan
J
Limaye
Sewanti
S
Kaushik
Neeraj
N
D000741:Anemia, Aplastic / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D019804:Mesalamine / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D011994:Recombinant Proteins; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D019804:Mesalamine; D000069585:Filgrastim